Salvage Living Donor Liver Transplantation for HCC Beyond All Criteria Yield Equivalent Results to Milan Criteria
NCT04069416 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 241
Last updated 2019-08-28
Summary
The present study aims to evaluate the impact of expanding criteria beyond Milan on tumor recurrence and patient survival that will help identify the best selection criteria for HCC transplanted patients.
Conditions
Interventions
- PROCEDURE
-
living donor liver transplantation
liver graft from a living donor
Sponsors & Collaborators
-
Ain Shams University
lead OTHER
Eligibility
- Min Age
- 18 Years
- Max Age
- 70 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2004-01-31
- Primary Completion
- 2015-12-31
- Completion
- 2019-01-31
More Related Trials
-
TACE/HAIC Combined With Lenvatinib and Sintilimab in Neoadjuvant Therapy for Intermediate-stage HCC
NCT05250843 ·Status: RECRUITING ·Phase: PHASE2/PHASE3
-
Multi-center Clinical Application of Hangzhou Criteria in Liver Transplantation for Hepatocellular Carcinoma
NCT03985644 ·Status: UNKNOWN
-
Relenvatinib in the Tatment of Recurrence of Hepatocellular Carcinoma After Liver Transplantation
NCT04237740 ·Status: UNKNOWN ·Phase: PHASE3
-
Transfemoral Versus Transradial Approach in Transarterial Chemoembolization of Hepatocellular Carcinoma
NCT06543030 ·Status: NOT_YET_RECRUITING
-
The Intention-to-treat Effect of Bridge Therapies in the Setting of Milan-in Patients
NCT03723304 ·Status: COMPLETED
-
Microwave Ablation Simultaneously Combined With Lenavatinib for Recurrent Hepatocellular Carcinoma
NCT05444478 ·Status: RECRUITING ·Phase: NA
-
Efficacy and Safety of Lenvatinib as a Conversion Therapy for HCC
NCT04241523 ·Status: UNKNOWN ·Phase: PHASE2
-
Sorafenib Versus Best Supportive Care in Egyptian Hepatocellular Carcinoma Patients.
NCT02971696 ·Status: COMPLETED ·Phase: PHASE3
-
Neoadjuvant and Adjuvant Lenvatinib in HCC Patients Treated by Percutaneous Ablative
NCT05113186 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Lenvatinib Combined With TACE to Prevent the Recurrence in High-risk Patients With Hepatocellular Carcinoma
NCT03838796 ·Status: UNKNOWN ·Phase: NA
-
FOLFOX Plus Lenvatinib Adjuvant Therapy for Hepatocellular Carcinoma Post-Liver Transplantation
NCT06409637 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1/PHASE2
-
Efficacy and Safety of ALSS Treatment for ICIs-LF in Patients With HCC
NCT05484908 ·Status: RECRUITING ·Phase: NA
-
Adjuvant Lenvatinib Prevents Recurrence of High-risk Patients With HBV-related HCC After Liver Transplantation
NCT04415567 ·Status: COMPLETED
-
HAIC Plus Lenvatinib vs HAIC Plus Sorafenib for Advanced HCC
NCT03775395 ·Status: UNKNOWN ·Phase: PHASE3
-
Pembrolizumab and LENvatinib in Participants With Hepatocellular Carcinoma (HCC) Before Liver Transplant
NCT04425226 ·Status: UNKNOWN ·Phase: NA
-
Lenvatinib Therapy in HCC Patients After LDLT
NCT05572528 ·Status: RECRUITING
-
Living Donor Liver Transplantation for Intrahepatic Cholangiocarcinoma
NCT06539377 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Atezolizumab and Bevacizumab Pre-Liver Transplantation for Patients With Hepatocellular Carcinoma Beyond Milan Criteria
NCT05185505 ·Status: RECRUITING ·Phase: PHASE4
-
Lenvatinib Treatment in Waiting List of Liver Transplantation After TACE Failure in Patients With Hepatocellular Carcinoma
NCT05901194 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
Lenvatinib Following Liver Transplantation in Patients of Hepatocellular Carcinoma With Portal Vein Tumor Thrombus
NCT04319484 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2/PHASE3
-
Lenvatinib Combined with Tislelizumab and TACE Applied As Neoadjuvant Regimen for the Patients of CNLC Stage IB and IIA Hepatocellular Carcinoma with High-risk Recurrence Factors
NCT05920863 ·Status: RECRUITING ·Phase: PHASE2
-
Study of Lenvatinib (E7080) in Participants With Advanced Hepatocellular Carcinoma (HCC)
NCT00946153 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Liver Resection Versus Transarterial Chemoembolization for the Treatment of Intermediate-stage Hepatocellular Carcinoma
NCT02755311 ·Status: UNKNOWN ·Phase: PHASE3
-
Clinical Study on the Effectiveness and Safety of Lenvatinib As Adjuvant Treatment for Patients with High-risk Recurrence of Hepatocellular Carcinoma After Surgery
NCT06762782 ·Status: RECRUITING ·Phase: PHASE2
-
Single Session Combined Locoregional Therapies for Hepatocellular Carcinoma
NCT02646137 ·Status: UNKNOWN ·Phase: PHASE3